Trial sequential analysis of P2Y12 inhibitor monotherapy after a short course of DAPT and standard DAPT for pre-specified endpoints. The plots show the trial sequential analysis of pre-specified endpoints, highlighted by specific boxes. The blue horizontal line within boundaries highlights the variability of treatment effect estimate with the cumulative number of patients, with the vertical line showing the threshold of patients needed to determine conclusiveness for benefit, futility or harm. Upper boundaries delimit the zone for benefit, while lower boundaries delimit the zone for harm and inner boundaries delimit the zone for futility. Conclusiveness for futility, benefit or harm means that performing another trial comparing the same treatment and control in a similar population will lead to similar conclusion, without substantially advancing the overall evidence on the topic. Abbreviations: DAPT, dual antiplatelet therapy; MACE, major adverse cardiovascular events; NACE, net adverse cardiovascular events.
